ERBB2 and neoplasm: Other examples aimed at increasing tumour rejection given in combination with standard cancer treatments (Criscitiello et al. 2014a) include trastuzumab + anti-PD-1 therapy for HER2+ metastatic patients (PANACEA) and nelipepimut-S + trastuzumab (Mittendorf et al. 2015).